Incretin-based therapies like semaglutide and tirzepatide have taken the world by storm - splashed across headlines, hailed as game-changers, and now likely being discussed over brunch. But beneath the hype lies important clinical nuance, especially when they cross paths with HRT.
Both semaglutide and tirzepatide are once-weekly injections approved in the UK for treating obesity and type 2 diabetes. They are agonists of GLP-1, which is an incretin hormone, helping to: increase satiety, reduce our appetite, reduce glucagon secretion, slow gastric emptying, and tirzepatide goes the extra mile as it is also a GIP analogue to enhance insulin secretion further.
Now, meet Maria, a 50-year-old lawyer managing her menopausal symptoms with oral utrogestan and transdermal oestrogen. All is well at her 3-month HRT review… until she casually mentions she's now using tirzepatide from a reputable private clinic. (Cue the internal alarm bells)
As of December 2024, over 500,000 individuals in the UK were estimated to be accessing incretin-based therapies privately. Recent projections indicate this figure may now exceed 1 million, with the majority obtaining treatment through online providers.
Why the Concern?
Incretin-based therapies like tirzepatide delay gastric emptying. This can interfere with drug absorption, a fact we already know from data showing up to a 66% reduction in peak levels of the combined oral contraceptive (COC). [Read Dr Rob Walker’s brilliant Blog on contraception while on tirzepatide]. So, if tirzepatide can do that to COCs, what might it do to oral progestogens like utrogestan? (The million-dollar question)
What's the Risk?
While specific data for HRT is lacking, extrapolated evidence suggests that delayed gastric emptying could reduce oral progesterone absorption, potentially compromising endometrial protection. And in women who have obesity, this risk becomes even more clinically significant.
Thankfully, the British Menopause Society (BMS) has produced clear, pragmatic guidance for how to manage patients like Maria who are taking oral utrogestan with transdermal oestrogen alongside incretin-based therapies:
Practical Recommendations:
And don’t forget about oestrogen: transdermal oestrogen administration is preferred when using incretin-based therapies, as it bypasses absorption issues and reduces VTE risk (always a bonus).
In summary, incretin-based therapies are revolutionising metabolic care, but they introduce new complexities in HRT management. Until we have stronger data, the key is informed counselling, evidence-based pragmatism, and shared decision-making with patients.
You can quickly add CPD to your account by writing a reflective note about the ‘Doctor, I’m on Mounjaro – will it interfere with my HRT?’ post you've read.
Log in to your NB Dashboard and use the 'Add Reflective Note' button at the bottom of a blog entry to add your note.